<DOC>
	<DOCNO>NCT00839917</DOCNO>
	<brief_summary>This study compare ProQuad™ concomitant administration M-M-R™ II Varivax™ respect immunogenicity , safety tolerability . The primary hypothesis test antibody response rate measles , mumps , rubella , varicella 6 week vaccination ProQuad™ non-inferior antibody response rate vaccination concomitant M-M-R™ II Varivax™ .</brief_summary>
	<brief_title>A Study ProQuad™ Healthy Children Korea ( V221-023 )</brief_title>
	<detailed_description />
	<mesh_term>Measles</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subject good health Subject negative clinical history measles , mumps , rubella , varicella zoster Subject previously receive measles , mumps , rubella and/or varicella vaccine , either alone combination Subject congenital acquire immune deficiency , neoplastic disease depress immunity Subject history seizure disorder Subject exposure measles , mumps , rubella , varicella and/or zoster last 4 week Subject receive inactivated vaccine within past 14 day Subject receive live vaccine within past 30 day Subject receive immune globulin within past 5 month Subject recent history fever ( within last 72 hour )</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>23 Months</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Measles</keyword>
	<keyword>Mumps</keyword>
	<keyword>Rubella</keyword>
	<keyword>Varicella</keyword>
</DOC>